Auto-generated from public data. Not the firm's stated position.
Nxt2b appears to focus on early-stage life sciences companies in Northern Europe, with particular emphasis on diagnostic and therapeutic innovations in the biotech and healthtech sectors. Recent portfolio activity suggests a concentration in companies developing novel diagnostic platforms and immunotherapy approaches, typically deploying €1.5M to €3.0M per investment at Series A and Series B stages.
Generated 14 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.